How a mouse-derived antibody became a cornerstone of modern autoimmune disease treatment

Health · Published 3 October 2026 Swipe more like this →

In short: Infliximab is a chimeric monoclonal antibody that revolutionized the management of conditions like Crohn's disease and rheumatoid arthritis. By neutralizing the inflammatory cytokine TNF, this laboratory-engineered protein offers relief where traditional therapies fail, though it carries significant risks that require careful medical monitoring and strategic patient selection.

Developed by Junming Le and Jan Vilček at the New York University School of Medicine in collaboration with Centocor, infliximab represents a sophisticated feat of biotechnology. Because early mouse-derived antibodies triggered human immune reactions, scientists replaced mouse common domains with human antibody sequences. This hybrid structure, known as a chimeric monoclonal antibody, allows the drug to bind to and neutralize tumor necrosis factor (TNF), a chemical messenger that drives autoimmune inflammation.

The clinical utility of infliximab is broad, spanning Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. In Crohn's disease, it has proven particularly effective for closing fistulae—abnormal connections between the bowel and skin. Trials like ACCENT 1 and ACCENT 2 established its role in inducing and maintaining remission, often leading gastroenterologists to adopt a top-down approach, using the drug early to avoid the side effects of long-term steroid use.

Despite its efficacy, infliximab is not without peril. As a potent immunosuppressant, it increases the risk of serious infections and, in some cases, life-threatening conditions like hepatosplenic T-cell lymphoma. Because the body can develop antibodies against the drug, which reduces its effectiveness, clinicians often combine it with other immunosuppressants like methotrexate. While biosimilars have expanded access since the first approvals in the late 1990s, the drug remains a complex tool that demands a balance between aggressive disease control and the management of severe adverse effects.

The mechanism of action distinguishes infliximab from other TNF inhibitors. Unlike etanercept, which is a receptor-construct fusion protein, infliximab is a true antibody capable of lysing cells involved in the inflammatory process. This unique ability to neutralize both soluble and transmembrane forms of TNF, combined with its capacity to bind receptor-bound TNF, underscores why it remains a primary medical therapy for challenging manifestations like perianal fistulizing Crohn's disease.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• The molecular decoy that calms an overactive immune system
• Tumor necrosis factor is a double-edged sword that both heals and destroys tissues.
• How a single molecular switch can silence chronic systemic inflammation
• How scientists learned to hack the immune system to create antibodies
• The biological master switch that can trigger or tame systemic inflammation
• One flu subtype, H1N1, lies behind three pandemics across a century
• Roughly one person in six faces infertility at some point in life
• When your abdominal wall fails, part of your intestine may slip into the groin.
• How a global chemical giant became a major player in medical research funding
• Injury responses unite animals from worms to vertebrates
• In situ: the Latin phrase used in more than 910,000 scientific papers
• Some insomniacs sleep for hours yet swear they were awake all night

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics